Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RARE Analyst Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RARE Stock 12 Month Forecast
Average Price Target
$85.86
▲(183.27% Upside)
| Highest Price Target$128.00 | Average Price Target$85.86 | Lowest Price Target$35.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$80
Buy
163.94%
Upside
Reiterated
09/09/25
William Blair
―
Buy
―
Reiterated
09/09/25
Bank of America Securities
$79
Buy
160.64%
Upside
Reiterated
09/09/25
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic DevelopmentsWe hosted and VP of to discuss how the company is thinking about near-term pipeline catalysts. Our conversation primarily focused on the pivotal OI program with Crombez continuing to highlight confidence in a successful final analysis (expected around year-end). He commented the extra 6-mos of treatment should improve the study’s odds of achieving stat sig, noting success at the 2 nd interim would have required a stronger treatment effect than the ph 2. Mgmt also reiterated that RARE remains blinded to the data with no knowledge of how close they were to hitting at the 2 nd interim. RARE was only informed of the total fracture number, which was in-line with modeled expectations, and safety with setrusumab continuing to be well tolerated.
Leerink Partners
―
Buy
―
Reiterated
09/08/25
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy RatingWe think these data confirm that the US patients were managed relatively conservatively in the blinded portion, with the cornstarch adjustments hindered by a third-party physician that had to guide the titration (see here for more detail). Additionally, these results also suggest that DTX401 is a much more capable drug than the Street assumes, with efficacy reaching curative levels in this burdensome disease.
Cantor Fitzgerald
$105
Buy
246.42%
Upside
Reiterated
09/04/25
Evercore ISI
$70
Buy
130.95%
Upside
Initiated
08/22/25
Piper Sandler
$105
Buy
246.42%
Upside
Reiterated
08/08/25
J.P. Morgan
$116→$125
Buy
312.41%
Upside
Reiterated
08/08/25
Truist Financial
―
Buy
―
Reiterated
08/07/25
Canaccord Genuity
$136→$128
Buy
322.30%
Upside
Reiterated
08/07/25
TD Cowen
$86
Buy
183.73%
Upside
Reiterated
08/06/25
RBC Capital
$77
Buy
154.04%
Upside
Reiterated
08/06/25
Morgan Stanley
$65→$55
Buy
81.46%
Upside
Reiterated
07/13/25
Wedbush
$39→$35
Hold
15.47%
Upside
Reiterated
07/10/25
Goldman Sachs
$82
Buy
170.54%
Upside
Reiterated
07/10/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$80
Buy
163.94%
Upside
Reiterated
09/09/25
William Blair
―
Buy
―
Reiterated
09/09/25
Bank of America Securities
$79
Buy
160.64%
Upside
Reiterated
09/09/25
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic DevelopmentsWe hosted and VP of to discuss how the company is thinking about near-term pipeline catalysts. Our conversation primarily focused on the pivotal OI program with Crombez continuing to highlight confidence in a successful final analysis (expected around year-end). He commented the extra 6-mos of treatment should improve the study’s odds of achieving stat sig, noting success at the 2 nd interim would have required a stronger treatment effect than the ph 2. Mgmt also reiterated that RARE remains blinded to the data with no knowledge of how close they were to hitting at the 2 nd interim. RARE was only informed of the total fracture number, which was in-line with modeled expectations, and safety with setrusumab continuing to be well tolerated.
Leerink Partners
―
Buy
―
Reiterated
09/08/25
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy RatingWe think these data confirm that the US patients were managed relatively conservatively in the blinded portion, with the cornstarch adjustments hindered by a third-party physician that had to guide the titration (see here for more detail). Additionally, these results also suggest that DTX401 is a much more capable drug than the Street assumes, with efficacy reaching curative levels in this burdensome disease.
Cantor Fitzgerald
$105
Buy
246.42%
Upside
Reiterated
09/04/25
Evercore ISI
$70
Buy
130.95%
Upside
Initiated
08/22/25
Piper Sandler
$105
Buy
246.42%
Upside
Reiterated
08/08/25
J.P. Morgan
$116→$125
Buy
312.41%
Upside
Reiterated
08/08/25
Truist Financial
―
Buy
―
Reiterated
08/07/25
Canaccord Genuity
$136→$128
Buy
322.30%
Upside
Reiterated
08/07/25
TD Cowen
$86
Buy
183.73%
Upside
Reiterated
08/06/25
RBC Capital
$77
Buy
154.04%
Upside
Reiterated
08/06/25
Morgan Stanley
$65→$55
Buy
81.46%
Upside
Reiterated
07/13/25
Wedbush
$39→$35
Hold
15.47%
Upside
Reiterated
07/10/25
Goldman Sachs
$82
Buy
170.54%
Upside
Reiterated
07/10/25
Best Analysts Covering Ultragenyx Pharmaceutical
1 Month
xxx
Success Rate
13/20 ratings generated profit
Average Return
+4.58%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +4.58% per trade.
3 Months
xxx
Success Rate
12/20 ratings generated profit
Average Return
+2.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.08% per trade.
1 Year
2 Years
xxx
Success Rate
11/29 ratings generated profit
Average Return
+8.31%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.93% of your transactions generating a profit, with an average return of +8.31% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RARE Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
24
22
35
27
27
Buy
1
1
6
10
12
Hold
9
12
13
12
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
34
35
54
49
49
Each month's total comprises the sum of three months' worth of ratings.
RARE Financial Forecast
RARE Stock Forecast FAQ
What is RARE’s average 12-month price target, according to analysts?
Based on analyst ratings, Ultragenyx Pharmaceutical’s 12-month average price target is 85.86.
What is RARE’s upside potential, based on the analysts’ average price target?
Ultragenyx Pharmaceutical has 183.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RARE a Buy, Sell or Hold?
Ultragenyx Pharmaceutical has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Ultragenyx Pharmaceutical’s price target?
The average price target for Ultragenyx Pharmaceutical is 85.86. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $128.00 ,the lowest forecast is $35.00. The average price target represents 183.27% Increase from the current price of $30.31.
The highest analyst price target is $128.00 ,the lowest forecast is $35.00. The average price target represents 183.27% Increase from the current price of $30.31.
What do analysts say about Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of RARE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.